Türeci Ö - Search Results

1

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months.

Thomas SJ, Moreira ED Jr, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Polack FP, Zerbini C, Bailey R, Swanson KA, Xu X, Roychoudhury S, Koury K, Bouguermouh S, Kalina WV, Cooper D, Frenck RW Jr, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Yang Q, Liberator P, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Gruber WC, Jansen KU; C4591001 Clinical Trial Group. Thomas SJ, et al. Among authors: tureci o. N Engl J Med. 2021 Nov 4;385(19):1761-1773. doi: 10.1056/NEJMoa2110345. Epub 2021 Sep 15. N Engl J Med. 2021. PMID: 34525277 Free PMC article. Clinical Trial.

2

Identification of tumor-associated autoantigens with SEREX.

Türeci O, Usener D, Schneider S, Sahin U. Türeci O, et al. Methods Mol Med. 2005;109:137-54. doi: 10.1385/1-59259-862-5:137. Methods Mol Med. 2005. PMID: 15585919

3

Tumor vaccination using messenger RNA: prospects of a future therapy.

Kreiter S, Diken M, Selmi A, Türeci Ö, Sahin U. Kreiter S, et al. Among authors: tureci o. Curr Opin Immunol. 2011 Jun;23(3):399-406. doi: 10.1016/j.coi.2011.03.007. Epub 2011 Apr 13. Curr Opin Immunol. 2011. PMID: 21497074 Review.

4

Targeting the tumor mutanome for personalized vaccination therapy.

Kreiter S, Castle JC, Türeci O, Sahin U. Kreiter S, et al. Among authors: tureci o. Oncoimmunology. 2012 Aug 1;1(5):768-769. doi: 10.4161/onci.19727. Oncoimmunology. 2012. PMID: 22934277 Free PMC article.

5

Antitumor vaccination with synthetic mRNA: strategies for in vitro and in vivo preclinical studies.

Diken M, Kreiter S, Selmi A, Türeci O, Sahin U. Diken M, et al. Among authors: tureci o. Methods Mol Biol. 2013;969:235-46. doi: 10.1007/978-1-62703-260-5_15. Methods Mol Biol. 2013. PMID: 23296938 Review.

6

Antigen identification using SEREX.

Sahin U, Türeci O. Sahin U, et al. Among authors: tureci o. Methods Mol Biol. 2013;1061:59-77. doi: 10.1007/978-1-62703-589-7_3. Methods Mol Biol. 2013. PMID: 23963930

7

mRNA-based therapeutics--developing a new class of drugs.

Sahin U, Karikó K, Türeci Ö. Sahin U, et al. Among authors: tureci o. Nat Rev Drug Discov. 2014 Oct;13(10):759-80. doi: 10.1038/nrd4278. Epub 2014 Sep 19. Nat Rev Drug Discov. 2014. PMID: 25233993 Review.

8

Retrieval of functional TCRs from single antigen-specific T cells: Toward individualized TCR-engineered therapies.

Omokoko T, Simon P, Türeci Ö, Sahin U. Omokoko T, et al. Among authors: tureci o. Oncoimmunology. 2015 Mar 19;4(7):e1005523. doi: 10.1080/2162402X.2015.1005523. eCollection 2015 Jul. Oncoimmunology. 2015. PMID: 26140230 Free PMC article.

9

Elimination of large tumors in mice by mRNA-encoded bispecific antibodies.

Stadler CR, Bähr-Mahmud H, Celik L, Hebich B, Roth AS, Roth RP, Karikó K, Türeci Ö, Sahin U. Stadler CR, et al. Among authors: tureci o. Nat Med. 2017 Jul;23(7):815-817. doi: 10.1038/nm.4356. Epub 2017 Jun 12. Nat Med. 2017. PMID: 28604701

10

Personalized vaccines for cancer immunotherapy.

Sahin U, Türeci Ö. Sahin U, et al. Among authors: tureci o. Science. 2018 Mar 23;359(6382):1355-1360. doi: 10.1126/science.aar7112. Science. 2018. PMID: 29567706 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

190 results

Search Page